AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-25 (Cancelled).

26. (New) A compound comprising:



,

wherein:

X is selected from the group consisting of CH_2SH, CH_2OH, NHOH, PO_3H_2, pyrazoles, imidazoles, oxazoles, isoxazoles, thiazoles, isothiazoles, triazoles, oxadiazoles and thiadiazoles; and

Y is selected from the group consisting of: COCZ, C(EWG)Z, SOCZ, SO_2CZ,



, , , , , , and ,

and pharmaceutically acceptable salts thereof, wherein:

EWG is an electron withdrawing group selected from the group consisting of CHO, COR, COOH, COOR, NO_2, CN, SOR, SO_2R, and SO_2OR;

Z is selected from the group consisting of chlorine, bromine, and iodine;

R is an alkyl or aryl group selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, s-butyl, t-butyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl; and

n is an integer 5 or less.

27. (New) A compound as recited in claim 26, wherein n is selected from 4 and 5.

28. (New) A pharmaceutical composition for treating microbial infections in a subject, comprising:

a therapeutically effective amount of an agent wherein the agent is selected from the compounds of claim 26, the agent being capable of altering an aspect of Type-I MetAP activity or structure in the subject so as to result in treatment of the bacterial infection; and

a pharmaceutically acceptable carrier.

29. (New) A pharmaceutical composition for treating bacterial infections in a subject, comprising:

a therapeutically effective amount of an agent wherein the agent is selected from the compounds of claim 26, the agent being capable of altering an aspect of Type-I MetAP activity or structure in the subject so as to result in treatment of the bacterial infection; and

a pharmaceutically acceptable carrier.

30. (New) A compound comprising a formula selected from the group consisting of:



,



,



,



,

and pharmaceutically acceptable salts thereof, wherein:

X is chlorine, bromine, or iodine;

EWG is an electron withdrawing group selected from the group consisting of CHO, COR, COOH, COOR, NO_2, CN, SOR, SO_2R, and SO_2OR;

R is an alkyl or aryl group selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, s-butyl, t-butyl, phenyl, substituted phenyl, naphthyl, and substituted naphthyl; and

n is an integer of 5 or less.

31. (New) A compound as recited in claim 30, wherein n is selected from 4 and 5.

32. (New) A pharmaceutical composition for treating bacterial infections in a subject, comprising:

a therapeutically effective amount of an agent wherein the agent is selected from the compounds of claim 30, the agent being capable of altering an aspect of Type-I

MetAP activity or structure in the subject so as to result in treatment of the bacterial infection; and

a pharmaceutically acceptable carrier.

33. (New) A compound comprising a formula selected from the group consisting of:



,



,



,



,



,



,



,

and pharmaceutically acceptable salts thereof, wherein:

EWG is an electron withdrawing group selected from the group consisting of CHO, COR, COOH, COOR, NO_2, CN, SOR, SO_2R, and SO_2OR;

R is an alkyl or aryl group selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, s-butyl, t-butyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl; and

n is an integer of 5 or less.

34. (New) A compound as recited in claim 33, wherein n is selected from 4 and 5.

35. (New) A pharmaceutical composition for treating bacterial infections in a subject, comprising:

a therapeutically effective amount of an agent wherein the agent is selected from the compounds of claim 33, the agent being capable of altering an aspect of Type-I MetAP activity or structure in the subject so as to result in treatment of the bacterial infection; and

a pharmaceutically acceptable carrier.